CAPTOPRIL

Post-LOE

Teva

ANDAORALTABLET

Approved

Feb 1996

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

CAPTOPRIL by Teva is mechanism of action the mechanism of action of captopril has not yet been fully elucidated. Approved for hypertension, diabetic nephropathy (proteinuria > 500 mg/day) in patients with type i insulin-dependent diabetes mellitus, retinopathy and 5 more indications. First approved in 1996.

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

Mechanism of Action The mechanism of action of captopril has not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. However, there is no consistent correlation between renin…

Indications (8)

Worked on CAPTOPRIL at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (3)

NCT04878315Phase 1Withdrawn

Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions

Started Feb 2022

Healthy Volunteers

NCT00917345N/AUnknown

Diagnosis of Primary Aldosteronism: Comparison of Post Captopril Active Renin Concentration and Plasma Renin Activity

Started Jan 2008

150 enrolled

Primary Aldosteronism

NCT00518765Phase 3Completed

Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet

Started Oct 2005

32 enrolled

Hypertension